Cytosolic phospholipase A2 from U937 cells: size of the functional enzyme by radiation inactivation

Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours

Human stomach tumours usually form more prostaglandins (PGs) than their associated normal mucosa/submucosa, but the mechanisms are not fully understood. The key enzymes are cytosolic phospholipase A2 (cPLA2, Mr 85,000) and the cyclo-oxygenases (COXs) which exist in constitutive (COX-1) and inducible forms (COX-2). In human stomach tumours and associated macroscopically normal tissues, we determined the fatty acid composition by gas chromatography, amounts of cPLA2, COX-1 and COX-2 by immunoblotting with specific antibodies and cPLA2 enzyme activity using a tritiated substrate. Although compared to normal mucosa there was less arachidonate in tumours (P < 0.05), the arachidonate/total fatty acid ratio was higher. Mean amounts of cPLA2 and COX-1 and cPLA2 activity were similar in tumours and normal mucosa. However, substantial amounts of COX-2 were found in the tumours but not in the mucosa, which may explain why many gastric tumours form increased amounts of PGs.

High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue

Human colon tumours usually form more prostaglandins (PGs) than associated normal tissues, but the mechanism(s) are not fully understood. We analysed fatty acid compositions, in particular arachidonate, and measured the amount and the activity of high molecular weight cytoplasmic phospholipase A2 (cPLA2) of these tissues. Total lipids extracted from homogenised surgical specimens were transesterified and fatty acids were analysed by gas chromatography. cPLA2 was separated by SDS-PAGE, Western-blotted, immunoblotted using a specific antibody to cPLA2 and semiquantified following enhanced chemiluminescence using a scanning densitometer. cPLA2 biological activity was also assayed using 1-stearoyl, 2-[1-14C]-arachidonyl, L-3-phosphatidylcholine. Compared with normal mucosa/submucosa, there was more total arachidonate in tumours (P < 0.01), and increased levels of cPLA2 occurred in 6 of 17 tumours. In conclusion, the higher amounts of tumour total arachidonate and the sometimes higher levels of cPLA2, might help to explain why some human colon tumours form increased amounts of PGs.

Inactivation of secretory phospholipase A2 by ionizing radiation

The extracellular phospholipase A2s (PLA2) from cobra venom, rattlesnake venom, and porcine pancreas were analyzed by radiation inactivation to determine their functional aggregation states. The analysis was performed in the presence of the protein transferrin at two different concentrations of PLA2: 5 micrograms/ml. The small size of these proteins necessitated the use of high radiation dosages. The catalytic activity of all samples decreased as a single exponential as a function of radiation dosage, to > 97% inactivation. Target size analysis of these curves yielded sizes corresponding to dimers for all three PLA2s, indicating that all three enzymes exist as dimers or larger aggregates under the conditions studied. An analysis of the amount of intact protein remaining by sodium dodecyl sulphate-polyacrylamide gel electrophoresis showed that the loss of protein also followed a dimeric size for all three PLA2s. The loss of protein as a dimer indicates that transfer of radiation energy is occurring between polypeptides.

Gravidin: an endogenous inhibitor of phospholipase A2

Gravidin is a recently discovered protein inhibitor of phospholipase A2 and therefore prostaglandin synthesis. Transformed or rapidly growing cells are unaffected by gravidin, but in slow-growing cells arachidonate release is inhibited. Gravidin may play a physiological role in pregnancy maintenance. This review summarizes our current knowledge of the properties and activity of gravidin.

Secretory phospholipase A2 is not required for arachidonic acid liberation during platelet activation

The subcellular localization of secretory phospholipase A2 (sPLA2) and cytosolic phospholipase A2 (cPLA2) in resting and activated platelets, and their involvement in arachidonic acid liberation during platelet activation, were studied. The amounts of sPLA2 and cPLA2 recovered were not modified during platelet activation. sPLA2 was mainly associated with the organelles of resting platelets (71% of total activity) and was released into the extracellular medium during cell activation (60% of total activity), whereas the majority of cPLA2 was localized in the cytosol of resting and activated platelets. The secretion of sPLA2 correlated with the release of ATP. sPLA2-depleted platelets aggregated as much as control platelets and produced similar amounts of thromboxane B2 upon thrombin activation. These results indicate that sPLA2 is not involved in the liberation of arachidonic acid during platelet activation.

Cytosolic phospholipase A2 from human monocytic cells: characterization of substrate specificity and Ca(2+)-dependent membrane association

A cytosolic phospholipase A2 (PLA2) has been purified to homogeneity from the human monocytic tumour cell line THP-1 by a combination of ion-exchange, heparin-agarose and hydrophobic-interaction chromatography and non-denaturing PAGE. The purified PLA2 exhibited a molecular mass of 100 kDa on SDS/PAGE, whereas non-denaturing PAGE showed a molecular mass of about 80 kDa. Investigation of the substrate specificity of PLA2 revealed no preference for arachidonic acid- over linoleic acid-containing phospholipids when labelled THP-1 membranes were used as substrate. Treatment of THP-1 cells for 1-72 h with the phorbol ester phorbol 12-myristate 13-acetate (PMA) led to a stable enzyme activation, which was also found after partial purification of PLA2 from PMA-stimulated THP-1 cells. The properties of the partially purified PLA2 from PMA-stimulated cells were compared with those of the PLA2 from unstimulated cells. Both enzymes showed an identical Ca(2+)-dependent enzyme activation (EC50 = 300 nM Ca2+). A significant difference was found in the Ca(2+)-dependent membrane association of the enzymes obtained from the two sources. PLA2 from PMA-stimulated cells showed membrane association of PLA2 activity at significantly lower Ca2+ concentrations (100-300 nM) compared with the PLA2 from unstimulated THP-1 cells (300-500 nM). The altered Ca(2+)-dependency was due to a stable modification of the enzyme. Changes in the ability of PLA2 to associate with cellular membranes may thus be regarded as an important molecular mechanism underlying the increase in fatty acid metabolism observed in activated cells.

Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2

A trifluoromethyl ketone analogue of arachidonic acid in which the COOH group is replaced with COCF3 (AACOCF3) was prepared and found to be a tight- and slow-binding inhibitor of the 85-kDa cytosolic human phospholipase A2 (cPLA2). Enzyme inhibition was observed when AACOCF3 was tested in assays using either phospholipid vesicles or phospholipid/Triton X-100 mixed micelles. The fact that the inhibition developed over several minutes in both assays establishes that AACOCF3 inhibits by direct binding to the enzyme rather than by decreasing the fraction of enzyme bound to the substrate interface. From the measured values of the inhibitor association and dissociation rate constants, an upper limit of the equilibrium dissociation constant for the Ca(2+).AACOCF3.PLA2 complex of 5 x 10(-5) mole fraction was obtained. Thus, detectable inhibition of cPLA2 by AACOCF3 occurs when this compound is present in the assay at a level of one inhibitor per several thousand substrates. Arachidonic acid analogues in which the COOH group is replaced by COCH3, CH(OH)CF3, CHO, or CONH2 did not detectably inhibit the cPLA2. The arachidonyl ketones AACOCF2CF3 and AACOCF2Cl were found by 19F NMR to be less hydrated than AACOCF3 in phospholipid/Triton X-100 mixed micelles, and compared to AACOCF3 these compounds are also weaker inhibitors of cPLA2. In keeping with the fact that cPLA2 displays substrate specificity for arachidonyl-containing phospholipids, the arachidic acid analogue C19H39COCF3 is a considerably less potent inhibitor compared to AACOCF3.(ABSTRACT TRUNCATED AT 250 WORDS)